UTERINE ANGIOMYOLIPOMA: A CASE REPORT, DIFFERENTIAL DIAGNOSIS WITH PECOMA AND REVIEW OF THE LITERATURE

Tihomir P. Totev, Svetlana A. Mateva, Margarita R. Nikolova, Grigor A. Gorchev

St. Marina Specialized Hospital of Obstetrics and Gynaecology – Pleven
1Department of General and Clinical Pathology, Medical University – Pleven
2Clinic of Oncogynaecology, University Hospital - Pleven

Summary

Angiomyolipomas are benign mesenchymal neoplasms, presenting with a variable mixture of adipose tissue, smooth muscle and vascular component. Although they are typically found in the kidneys, many cases of extrarenal angiomyolipomas have been reported. They are extremely rarely present in the uterus. We describe a case of a 56-year-old woman, operated on for leiomyoma. Total laparohysterectomy and bilateral adnexectomy was performed. After histological and immunohistochemical examination, the final diagnosis of uterine angiomyolipoma was made. Renal and extrarenal angiomyolipomas are compared in regard to clinical and morphological aspect and their difference from PEComas is discussed. PEComas have been defined during the last decade and there are still issues regarding terminological clarity and overlapping.

Key words: angiomyolipoma, PEComa, angiolipoleiomyoma

Introduction

Angiomyolipomas (AML) are benign mesenchymal neoplasms that present a variable mixture of adipose and smooth muscle with a well-expressed vascular component. They are usually located in the kidneys. However, other extrarenal localizations have been reported [1, 2]. Most renal AMLs can be diagnosed preoperatively by computer tomography and ultrasound [2]. Because of the benign nature of the lesion, treatment, especially for small and asymptomatic tumours, is conservative. Surgical treatment is applied when the neoplasms are larger than 4 cm or complications with a rupture have occurred [3]. Renal AMLs can be sporadic or combined with tuberous sclerosis (TS) – a hereditary autosomal dominant complex, presenting with multiple hamartomas in various internal organs [1, 2, 3]. In both cases, renal AMLs express melanocytic and smooth-muscle markers [1, 2]. The clinical presentation of uterine AMLs is variable, often similar to that of typical leiomyomas (LM) – menometrorrhagia, presence of pelvic mass, abdominal pain or even lack of symptoms [4, 5].
Sonography does not distinguish AMLs from uterine LMs but endovaginal sonography, combined with CT and MRI allows a more detailed preoperative diagnosis [4]. In most cases AMLs originate from the uterine body but cases have been reported of cervical localization [6], mostly in females over 40 [7]. They vary in size (2-16 cm) and are well-wrapped in a pseudocapsule [8]. Uterine AMLs are benign, and progression to malignancy has not been reported [9].

Case report

A 56-year-old patient presented with low abdominal pain. The gynaecological examination revealed a myomatous node on the anterior uterine wall. The patient underwent total laparohysterectomy and bilateral adnexectomy. The node was located in the submucosa of the anterior uterine wall. Macroscopically, it was soft, round, yellowish, 6 cm in diameter, with clearly-cut boundaries (Fig. 1). The adnexa had age-related alterations and inclusion cysts. Histology of the tumor proved three tissue components: smooth muscle fibers, mature adipose tissue and multiple thick-walled vessels (Fig. 2). No mitoses, atypical cell structures or necrotic changes were found. The smooth muscle component was immunoreactive to α-SMA (Fig. 3). Based on macroscopic, histological and immunohistological findings, the final diagnosis was AML, after ruling out PEComa.

Following uneventful recovery, the patient was discharged on the 6th postoperative day.

Discussion

Intrauterine AMLs are extremely rare, and are not officially listed in the WHO Classification of female reproductive system tumors [11]. When these are of intrauterine localization, they are reported as AMLs [1, 8-15], angiolipoleiomyomas (ALLM) [4, 7, 16, 17] or lipoleiomyomas with abnormal vessels [18]. They all present the same type of lesion, consisting of fatty tissue, smooth muscle and a well-expressed vascular component. There is no exact definition of the so-called “vascular component”. It usually includes descriptions of arteries as abnormal, small- to medium-sized, with varying thickness of the walls and a well-developed capillary network [7]. In the literature available,
intrauterine tumors with such features were first referred to as ALLM in a report by Sieinski in 1989 [17]. Since then, 17 cases of AMLs have been reported, including this one. These are presented on Table 1.

Table 1. Cases of AMLs reported in the literature

<table>
<thead>
<tr>
<th>No</th>
<th>Reference</th>
<th>Age of patient</th>
<th>Tumor/HMB45 reactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>[18] Sieinski 1989</td>
<td>52</td>
<td>ALLM/ not analyzed</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>52</td>
<td>ALLM/ not analyzed</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>57</td>
<td>ALLM/ not analyzed</td>
</tr>
<tr>
<td>4</td>
<td>[14] Laffargue et al. 1993</td>
<td>20</td>
<td>AML/ HMB 45-</td>
</tr>
<tr>
<td>5</td>
<td>[19] Shintaku 1996</td>
<td>67</td>
<td>lipoleiomyoma with abnormal arterial vessels/ not analyzed</td>
</tr>
<tr>
<td>6</td>
<td>[7] Huang et al. 2000</td>
<td>34</td>
<td>AML/ HMB 45-</td>
</tr>
<tr>
<td>7</td>
<td>[12] Chetty et al. 2000</td>
<td>52</td>
<td>AML/ not analyzed</td>
</tr>
<tr>
<td>8</td>
<td>[9] Yaegashi et al. 2001</td>
<td>40</td>
<td>AML/ HMB 45-</td>
</tr>
<tr>
<td>11</td>
<td>[8] Ren et al. 2004</td>
<td>40</td>
<td>AML/ HMB 45-</td>
</tr>
<tr>
<td>13</td>
<td>[10] Cho et al. 2009</td>
<td>62</td>
<td>AML/ HMB 45-</td>
</tr>
<tr>
<td>14</td>
<td>[17] Kajo et al. 2010</td>
<td>53</td>
<td>AML/ HMB 45-</td>
</tr>
<tr>
<td>15</td>
<td>[16] Ylmaz et al. 2013</td>
<td>44</td>
<td>AML/ HMB 45-</td>
</tr>
<tr>
<td>16</td>
<td>[15] Lee et al. 2013</td>
<td>41</td>
<td>AML/ not analyzed</td>
</tr>
<tr>
<td>17</td>
<td>Case presented 2014</td>
<td>56</td>
<td>AMJ/ HMB 45-</td>
</tr>
</tbody>
</table>

Apart from differences in the clinical presentation, other differences between renal and extrarenal AMLs have been found that can be useful in making the differential diagnosis. For example, renal and hepatic AMLs combine with tuberous sclerosis (TS) in 5-50% of the cases. However, this combination is not seen in the rest of extrarenal tumors [6]. Of the 17 cases of extrarenal tumors, shown on Table 1, a combination with TS was reported in only two patients [12, 14].

Immunoreactivity to HMB-45 has been reported for tumors of the colon, parametria and lymph nodes but it is not typical of uterine AMLs [6-8]. One of the 17 above mentioned cases of uterine AMLs was reported to be immunoreactive to HMB-45, and the remainder were not investigated [12]. The smooth muscle cells in the renal and hepatic tumors are epithelioid, whereas in the AMLs these cells are elongated.

Epithelioid AMLs (the term PEComas seems to be more appropriate, see below) are potentially malignant mesenchymal neoplasms, characterized mainly by proliferation of epithelioid cells. These cells are immunoreactive to melanocytic markers and are a monophasic, smooth muscle formation of a common triphasic neoplasm [19-21]. In more than 50% of the cases they are combined with TS. Most patients are symptomatic since the tumors are usually large and infiltrative [19].

During the last decade a family of tumors has been fully differentiated. They derive from perivascular epitheloid cells (PEC). These cells express both myogenic and melanocytic markers. The expression includes some forms of AMLs and lymphangioleiomyomatosis (LAM) as well as clear-cell “sugar” lung tumor, clear-cell myomelanocytic tumor of the falciform ligament and rare atypical tumors of other anatomical localizations [21-23]. The term PEComa was proposed by Zamboni in 1996 [23].

Most often, these tumors are located in the uterus and the retroperitoneal space [24]. The first intrauterine PEComa was described by Pea M. et al. in 1996 [25]. At present, nearly 50 cases of intrauterine PEComas have been reported, most of them described during the last decade. These cases include tumors, designated
as PEComas, perivascular epithelioid cell tumours, abdominopelvic sarcomas, mesenchymal neoplasms with HMB-positive epithelioid cells or 5 epithelioid AMLs [25-46]. The clinical symptoms are non-specific and variable, and the ultrasound image depends on the biological features of the tumour. Therefore, neither the clinical presentation nor the ultrasound findings are sufficient to make a preoperative diagnosis. Association with TS has been established in about 9% of the cases. In the largest group of 44 uterine PEComas investigated, 37 tumours were clinically followed up and 16 were proved as clinically aggressive [47]. In 2005, Folpe et al. proposed morphological criteria, including infiltrative growth, tumour size, nucleic polymorphism, cellularity, mitotic activity, necrosis and vascular invasion. According to these criteria, PEComas, irrespective of their localizations, have been classified as either benign, as such with uncertain malignant potential, or as malignant [34]. Applying the same morphological markers, other authors classify uterine PEComas as malignant or non-malignant [47]. These morphological markers have been used for too short to determine their reliability. In addition, the low incidence of PEComas makes the therapeutic approach to such cases difficult to specify. However, because of the unpredictable behaviour of the neoplasms in this group, some authors find it appropriate to plan for a long period of follow-up [21, 34, 46, 47]. Therefore, there exists a great variety of diversity of terms used to designate tumors belonging to one and the same pathomorphological group. On the other hand, the terms for morphologically different neoplasm overlap. All these practices result in a certain terminological confusion and make it difficult to choose an exact term for each tumor. This poses a serious problem, insofar as PEComas are neoplasms of uncertain malignant potential and their diagnosing is crucial. Moreover, because these neoplasms are likely to be combined with TS, patients need to have other internal organs investigated. For this purpose, it is very important to use the term PEComa for tumors, composed of only, or predominantly of epithelioid HMB-45+ cells [20, 46, 47]. Therefore, an epithelioid AML is in fact a kind of PEComa [46]. To avoid overlooking /omissions in diagnosing PEComas, all uterine mesenchymal tumors with predominantly epithelioid appearance should be tested with melanocytic markers or at least with HMB-45 [46, 47].

**Conclusion**

We believe that in the near future, with a sufficient number of cases registered, the issues concerning terminological problems, morphological criteria and therapeutic approach to PEComas will find their final solution.

**References**

7. Ren R, Wu HH. Pathologic quiz case a 40-year-old
35. Fukunaga M. Perivascular epithelioid cell tumor...